Jester H G
Dtsch Med Wochenschr. 1978 Dec 1;103(48):1922-5. doi: 10.1055/s-0028-1129368.
Plasminogen activator contains equimolar proportions of streptokinase and human plasminogen, and as proactivator-streptokinase complex it has activator properties. In nine patients with recent venous thromboses of the upper or lower limbs plasminogen activator treatment achieved complete recanalisation in 14 of 27 veins occluded by thrombosis and partially in six. Clotting tests indicated that activator treatment can be better controlled than streptokinase treatment.
纤溶酶原激活剂含有等摩尔比例的链激酶和人纤溶酶原,作为前激活剂 - 链激酶复合物,它具有激活剂特性。在9例近期发生上肢或下肢静脉血栓形成的患者中,纤溶酶原激活剂治疗使27条因血栓形成而闭塞的静脉中的14条完全再通,6条部分再通。凝血试验表明,激活剂治疗比链激酶治疗更容易控制。